LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

Veeva to Present at Upcoming Investor Conferences

June 05, 2023 | Last Trade: US$215.95 4.71 -2.13

PLEASANTON, Calif., June 5, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conferences:

  • William Blair 43rd Annual Growth Stock Conference, Chicago, IL. Brent Bowman, CFO, is presenting on Wednesday, June 7, 2023, at 10:00 a.m. Central Time.
  • Baird 2023 Global Consumer, Technology & Services Conference, New York, NY. Paul Shawah, EVP Commercial Strategy, is presenting on Thursday, June 8, 2023, at 7:55 a.m. Eastern Time.

The above presentations will be webcast. Links to the live and archived webcast will be available on Veeva's investor relations website at https://ir.veeva.com.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.

Investor Relations Contact:
Gunnar Hansen
Veeva Systems Inc.
267-460-5839
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Maria Scurry
Veeva Systems Inc.
781-366-7617
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page